LabRoots invites you to the 3rd Annual CRISPR Virtual Event! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision in gene editing, and using CRISPR for drug discovery.
The planning committee will bring together thought leaders from academia, trained researchers from clinical laboratories, and industry experts from pharmaceutical to biotech. Experts will share case studies, experiences, and new developments regarding best practices and address appropriate alternatives that are currently being developed.
CRISPR Applications in Biomedicine and Agriculture
CRISPR for Addressing COVID-19 Pandemic
Ethical, Social, and Legal Issues in CRISPR applications
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn, and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 CRISPR Virtual Event. Submission is free. Submit your abstract here.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Use #LRcrispr to follow the conversation!
POSTER SUBMISSION GUIDELINES
Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.
SUBMIT YOUR ABSTRACT
Enter the following information to this Submission Form:
All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.
If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.
Questions? Email Posters@LabRoots.com
Omar Abudayyeh, Ph.D., is a McGovern Institute Fellow at the Massachusetts Institute of Technology where he leads a lab on exploring microbial diversity for new biotechnological tools related to genome editing and gene delivery. He previously was at Harvard Medical School and the Harvard-MIT Health Sciences and Technology program as a graduate student. He completed his doctoral work in Feng Zhang’s lab at the Broad Institute of MIT and Harvard, where his research centered on novel CRISPR enzymes for applications in genome editing, therapeutics, and diagnostics. Dr. Abudayyeh’s work focused on uncovering novel CRISPR enzymes beyond Cas9 for biotechnological applications. He co-led the discovery and characterization of multiple landmark pieces of work, including the characterization of Cpf1 for novel genome editing applications and the first single-protein RNA-guided RNA-targeting enzyme C2c2/Cas13. His follow-up work on C2c2/Cas13 biology led to the development of SHERLOCK technology, and a new set of tools for precise editing of transcripts and visualizing them in mammalian cells with potential for RNA therapeutics. In recognition of his technology developments, Dr. Abudayyeh was recognized as 2018 Forbes 30 under 30 in Science and Health Care and Business Insider 30 under 30. Dr. Abudayyeh graduated from MIT in 2012 with a B.S. in mechanical engineering and biological engineering, where he was a Henry Ford II Scholar and a Barry M. Goldwater Scholar.
Adam Ameur is associate professor and senior bioinformatician at the SciLifeLab National Genomics Infrastructure in Sweden. His work is focused on technology development and novel sequencing applications for the study of human health and disease. Ongoing activities include the construction of a whole-genome reference dataset for genetic variation in the Swedish population, as well as introduction of long-read single molecule sequencing into clinical routine. Since 2017 he is also an adjunct researcher at Monash university in Melbourne, Australia.
Originally from San Diego, CA, Grace moved to North Carolina for college and graduated from University of North Carolina at Greensboro in 2013 with a B.S. in Biology (biotechnology concentration) with chemistry and anthropology minors. In 2018, they completed their PhD in Kris Wood’s lab at Duke University in the Molecular Cancer Biology program. Their work focused on utilizing functional genomics approaches to uncover novel vulnerabilities in cancers with intrinsic or acquired resistance to anti-cancer therapies. Following graduate school, Grace was a postdoctoral fellow at Stanford University in the Genetics Department where they worked closely with another postdoc to understand the genetic liabilities associated with 3D growth in cancer spheroid models. Currently, they are a scientist at an early stage drug development company that pairs multiplexed reporter assays and high-throughput chemistry to map chemical/biological interactions.
Kiana received her PhD in Biomedical Engineering at Rutgers University. She then continued her postdoctoral studies in bio-engineering at the UC Berkeley. She is a recipient of the National Institutes of Health postdoctoral training fellowship at the Buck Institute for Age Research and is a consultant for the Gates Foundation. Kiana runs the Cardea Innovation lab at the Keck Graduate Institute of Applied Life Sciences.
Dr. Gurpreet Balrey is the Head of Business for Europe, Middle East and Africa for the Genome Engineering and Modulation franchise at Merck. He attended the University of Nottingham for a Biotechnology degree followed by a PhD in Molecular Biology and Plant Genetic Engineering at the same University. Gurpreet has held various positions within the technical sales team during his 11 years with the company. He has particularly been involved in working with the Welcome Trust Sanger Institute to bring the arrayed whole genome libraries to market and more currently on our SygRNA® synthetic two part and single guide CRISPR RNA offering.
James Goldmeyer, PhD, Product Manager at Horizon Discovery. In his extended service with the company, James has led the development and commercial launch of numerous product lines. He currently has responsibility for the Functional Genomic Screening services and library offerings and is heavily involved in the development of novel applications and screening paradigms to support client research efforts. James works closely with an expert group of R&D scientists on innovative tools and services for gene modulation and engineering. James earned a doctorate degree in physiology and neurobiology at the University of Connecticut.
Jonathan Gootenberg, Ph.D. draws from fundamental microbiology to engineer new molecular tools. These tools, including the popular genome editing system CRISPR, allow for unprecedented manipulation and profiling of cellular states in the body, and have multiple applications in basic science, diagnostics, and therapeutics. Dr. Gootenberg uses gene editing, gene delivery, and cellular profiling methods to understand the changes that occur in the brain and other organs during aging, with the goal of generating new therapies for degenerative disease. Dr. Gootenberg earned his bachelor’s degree in mathematics and biological engineering at MIT and received his PhD in Systems Biology from Harvard University, during which he conducted research with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute of MIT and Harvard. During his graduate work, Gootenberg focused on the development of molecular technologies for treating and sensing disease states, crossing disciplines by utilizing novel computational techniques, microbiology, biochemistry, and molecular biology to uncover new CRISPR tools, including Cas12 and Cas13. He and his co-authors developed Cas13 into a toolbox with uses in fundamental research, therapeutics, and diagnostics. These applications include RNA knockdown, imaging, the base editing platform REPAIR, and the sensitive, specific, and portable diagnostic platform SHERLOCK. He is one of the first members of the McGovern Institute Fellows program, which supports the transition to independent research for exceptional recent PhD graduates.
Ashley Jacobi is a Staff Scientist in the Molecular Genetics Research and Development group at IDT. Ashley has been with IDT for 14 years, and during that time, she has been an author on 18 manuscripts published in peer-reviewed journals, contributed to numerous patent applications, and has presented at a wide variety of international biomedical research conferences. She has been conducting research in RNAi and antisense oligo technologies, but more recently has been focusing on the development of novel CRISPR RNA sequences and modification patterns that allow for more efficient and specific cleavage by the S.p. Cas9 and A.s. Cas12a CRISPR nucleases.
Nandini Krishnamurthy leads the Microbial Applications Development team at Inscripta. She brings greater than 15 years of research and development experience leading at the interface of experimental and computational biology. Most recently she served as Senior Research Manager, at Corteva Agriscience responsible for delivering innovative solutions in diverse trait areas using genome editing technology in multiple crops to drive differential advantage in the market. Prior to this, she has served in various positions at DuPont Pioneer, Genentech, the University of California, Berkeley, and Rockefeller University. Nandini holds a PhD in Plant Biology from Texas A&M University.
Shondra Pruett-Miller, Ph.D. is an Assistant Member in the Department of Cell and Molecular Biology, the Founding Director of the Center for Advanced Genome Engineering (CAGE), and the Associate Director of Shared Resoucres for the Comprehensive Cancer Center at St. Jude Children’s Research Hospital in Memphis, TN. Shondra completed her Ph.D. in Cell and Molecular Biology from The University of Texas Southwestern Medical Center in August 2008. While at UT Southwestern, she worked in Matthew Porteus’ lab on the optimization of zinc finger nucleases for use in mammalian cells. After graduate school, she was recruited to Sigma-Aldrich as a Senior Scientist in R&D working on their CompoZr ZFN technology. In 2012, she returned to academia as the Founder and Director of the Genome Engineering and iPSC Center (GEiC) at Washington University School of Medicine in St. Louis. In 2017, she joined the Faculty at St. Jude Children’s Research Hospital where she established and is directing the Center for Advanced Genome Engineering (CAGE). Shondra has overseen the creation of over 1000 custom edited clonal cell lines, more than 250 custom edited preclinical animal models, and over 50 custom pooled gRNA screens.
Dr. Niren Murthy is a professor in the Department of Bioengineering at the University of California at Berkeley. Dr. Murthy’s scientific career has focused on the molecular design and synthesis of new materials for drug delivery and molecular imaging. The Murthy laboratory developed the hydrocyanines in 2009, which are now one of the most commonly used probes for imaging reactive oxygen species and commercially available from multiple sources. The Murthy laboratory has developed several new nanoparticulate technologies for drug delivery, such as the polyketals, which have been used by numerous laboratories to enhance the delivery of small molecules and proteins. The Murthy laboratory has been recently focused on developing non-viral delivery vehicles that can deliver Cas9 protein, gRNA and Donor DNA in vivo. Dr. Murthy received the NSF CAREER award in 2006, and the 2009 Society for Biomaterials Young Investigator Award.
Dr. Peter Romanienko obtained his PhD training from Cornell Graduate School of Medical Sciences/Sloan Kettering Institute working on DNA repair in Dr. Maria Jasin's laboratory and then continued working on mechanisms of DNA damage response in vivo in Dan Camerini-Otero's laboratory at NIH. After the NIH, he joined Memorial Sloan Kettering Cancer Center (MSKCC) and instituted a comprehensive mouse colony management service and supported the generation of new GEMMs. While at MSKCC, he introduced the use of gene editing to make mouse models, first with TALENS and then CRISPR-Cas9. After gaining extensive experience applying these novel methods that have revolutionized modern research, he moved to Rutgers Cancer Institute to setup and run the Genome Editing Shared Resource (GESR). While at Rutgers, the GESR has generated well over 120 novel mouse lines using CRISPR-Cas9 and also works to develop and introduce new methodologies.
Dr. Marka van Blitterswijk is an Assistant Professor and Associate Consultant in the Department of Neuroscience at Mayo Clinic. She obtained her MS degree in Bioinformatics at Johns Hopkins University (Baltimore, MD). Dr. Van Blitterswijk completed her MD and PhD degree at Utrecht University (the Netherlands). Her laboratory at Mayo Clinic focuses on the discovery of novel genes, disease modifiers, therapeutic targets, and biomarkers for neurodegenerative diseases. She is particularly interested in the most frequent genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD): a C9orf72 repeat expansion. Her laboratory employs innovative patient-oriented strategies. As a geneticist and bioinformatician, she has broad experience using various genomic technologies and analyses, such as long-read sequencing and machine learning.
Minja Velimirovic is a PhD candidate working in laboratory of Dr Richard Sherwood Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School. She joined the team there in January of this year, after spending prior year doing translational research with the special emphasis on the implementation of genome editing technologies for therapeutic purposes, at University of Laval in Quebec. Minja's research focuses on utilizing a suite of novel high-throughput genomic perturbation platforms, CRISPR-based genome editing and single cell RNA-sequencing.
At MicroGEM, we have re-invented nucleic acid extraction. We replace traditional extraction methods with a temperature-driven, enzymatic approach, enabling high-quality extracts from low abundance transcripts and small sample volumes. Leveraging our prepGEM Universal thermophilic ...See more See less
Sony Biotechnology Inc. is dedicated to helping researchers working across different life science disciplines to achieve the best scientific results. By leveraging Sony's vast know-how in electronics innovation and design we offer next-generation cell analysis systems to ...See more See less
Millipore Sigma is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis ...See more See less
GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a ...See more See less
Horizon Discovery Group PLC is a world leader in the utilization of gene editing and gene modulation technologies to support the greater understanding of gene function, the genetic drivers behind human disease and the development of molecular, cell and gene therapies to enable ...See more See less
Inscripta is developing the world's first benchtop platform for scalable digital genome engineering. The company's advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel ...See more See less
Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors ("Cardean transistors"). Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical ...See more See less
For over 30 years, IDT has enabled discovery by adhering to the highest manufacturing standards, even as we continue to lower prices and improve delivery speed. Our full-workflow CRISPR solutions include potent Cas9 and Cas12a nucleases (for GC-rich or AT-rich genomes), custom ...See more See less
With a portfolio of more than 4,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in ...See more See less
OriGene Technologies was founded as a research tool company focused on the creation of the large commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based ...See more See less
As the scientific community races to solve this evolving global health crisis, Twist Bioscience is proud to carry on as an active partner for all of your research needs. Twist's unique silicon-based DNA writing platform allows for the rapid development of NGS panels for viral ...See more See less
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
Dr. Manush Saydmohammed is currently Research Instructor at the University of Pittsburgh, PA. Prior to this, he worked as Research Associate at Uniformed Services University of the Health Sciences, Bethesda MD and as Japan Society for Promotional Sciences Post Doctoral Fellow at ...See more See less
Dr. Muhamuda Kader, an immunologist by background, is currently working as a Research Faculty at the University of Pittsburgh, PA. After her bachelor's and master's in microbiology, and Ph.D in Neurovirology from the National Institute of Mental Health and Neuroscience ...See more See less
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events